However, experts say these funds can prove to be good contra bets for investors willing to hold them for three-five years. One good reason for investing now is that the negatives are already factored into the prices. Indian companies have got better at handling USFDA strictures.
Moreover, Indian pharma companies are global leaders in generics. One in every three generic pill consumed in the US is supplied by an Indian company. And now they are also venturing into complex generics.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in